Analyst Ratings January 27, 2026

Truist Cuts Brown & Brown Price Target, Cites Slower Organic Growth and Howden Personnel Headwinds

Analyst keeps Buy rating while trimming 2026 EPS and modeling a conservative 2027 outlook tied to a 15x EBITDA multiple

By Leila Farooq BRO
Truist Cuts Brown & Brown Price Target, Cites Slower Organic Growth and Howden Personnel Headwinds
BRO

Truist Securities lowered its price objective for Brown & Brown (NYSE: BRO) from $105.00 to $100.00 but left its Buy recommendation intact. The revision follows a reduction in Truist's 2026 EPS forecast to $4.55 from $4.75, reflecting expected weaker organic growth and some topline pressure related to personnel losses at Howden. Truist also flagged higher shares outstanding and set a 2027 EPS forecast of $5.05, anchoring the new target to a 15 times multiple of its 2027 EBITDA estimate of $2.76 billion. Separately, Brown & Brown's Q4 2025 results showed an EPS beat of $0.93 versus expectations of $0.91 and revenue of $1.6 billion below the $1.65 billion estimate.

Key Points

  • Truist reduced its price target on Brown & Brown to $100.00 from $105.00 but maintained a Buy rating.
  • Truist lowered its 2026 EPS estimate to $4.55 from $4.75, citing lower organic growth and topline pressure from Howden personnel losses; it set 2027 EPS at $5.05.
  • The new target is based on a 15x multiple of Truist's 2027 EBITDA estimate of $2.76 billion; Brown & Brown's Q4 2025 showed EPS of $0.93 (above $0.91 estimate) and revenue of $1.6 billion (below $1.65 estimate).

Truist Securities has trimmed its price target for Brown & Brown (NYSE: BRO) to $100.00 from $105.00, while retaining a Buy rating on the insurance brokerage. The broker's reduced target follows adjustments to its near-term earnings outlook and considerations around share count.

In its updated forecasts, Truist lowered its 2026 earnings per share estimate to $4.55 from $4.75. Analysts attributed the cut to expectations of reduced organic growth and modest topline headwinds tied to personnel losses at Howden. Despite these downgrades, the broader analyst consensus still points to profitability, with a consensus EPS forecast of $3.89 for 2026.

Truist also called out higher shares outstanding as a factor influencing its revised outlook. For 2027, the firm established an EPS forecast of $5.05 per share for Brown & Brown.

The newly set price target rests on a target multiple of 15 times Truist's 2027 EBITDA estimate of $2.76 billion. Truist notes that this multiple places Brown & Brown slightly ahead of the group average on this year’s EBITDA, while still just under the company's eight-year EBITDA multiple norm of 15.5 times, according to the firm's analysis.


Brown & Brown's most recent quarterly results painted a mixed picture. For the fourth quarter of 2025, the company reported earnings per share of $0.93, outpacing analyst expectations of $0.91 and yielding a 2.2% positive surprise. On the revenue side, however, the company posted $1.6 billion versus the $1.65 billion that had been anticipated, falling short of estimates.

Those results highlight a divergence between profit performance and top-line generation: Brown & Brown managed to beat EPS expectations while missing on revenue, underscoring some ongoing concerns about growth despite the company’s ability to deliver slightly stronger-than-expected quarterly earnings.

Investors and market participants will weigh Truist's valuation approach - a 15 times multiple on projected 2027 EBITDA - against the firm's reference points, including the stated eight-year norm of 15.5 times. For now, Truist's rating remains constructive even as its model incorporates slower organic growth, Howden-related headwinds, and a larger share base into the forecast framework.

Risks

  • Lower organic growth and personnel-related topline pressure at Howden could limit revenue expansion - this affects insurance brokerage and broader financial services sectors.
  • An increased share count could dilute per-share metrics and weigh on valuation multiples - relevant to equity investors and market participants.
  • Revenue misses, despite EPS beats, indicate potential limits to growth sustainability and could influence investor sentiment in the insurance and broker-dealer sectors.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026